The evolving place of vagus nerve stimulation therapy
- 24 September 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (6_suppl_4) , S1-S2
- https://doi.org/10.1212/wnl.59.6_suppl_4.s1
Abstract
Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.Keywords
This publication has 8 references indexed in Scilit:
- The Expert Consensus Guideline Series: Treatment of EpilepsyEpilepsy & Behavior, 2001
- Surgery for epilepsySeizure, 2001
- A Randomized, Controlled Trial of Surgery for Temporal-Lobe EpilepsyNew England Journal of Medicine, 2001
- Vagus nerve stimulation and the ketogenic dietNeurologic Clinics, 2001
- Message from the EditorEpilepsy & Behavior, 2001
- EpilepsyNeurologic Clinics, 2001
- Long‐Term Retention Rates of Lamotrigine, Gabapentin, and Topiramate in Chronic EpilepsyEpilepsia, 2000
- Early Identification of Refractory EpilepsyNew England Journal of Medicine, 2000